Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.62 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950159 | 0.83 | SLC6A4 (0.72) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL2951055 | 0.79 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL2943873 | 0.78 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2951070 | 0.78 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2948711 | 0.78 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2941780 | 0.77 | SLC6A4 (0.66) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL2947610 | 0.77 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL2946646 | 0.77 | SLC6A4 (0.85) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL2948706 | 0.76 | SLC6A2 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2951320 | 0.76 | SLC6A4 (0.70) | SLC6A4SLC6A3SLC6A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | claimed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | CYP3A7, CYP3A5, HTR7 | SLC6A4 1438/4885SLC6A3 1264/4885SLC6A2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.